Metsera, Inc.
MTSR
Rang in aandelen
#2575
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aandeelprijs
$70.50
Laatst gesynchroniseerd: 2025-11-14
Marktkapitalisatie
$7.33B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
33.60%
Land
US
Handel Metsera, Inc. (MTSR)
Categorie
Healthcare
Dividendrendementgeschiedenis voor Metsera, Inc. (MTSR)
Het dividendrendement (TTM) van Metsera, Inc. (aandelsymbool: MTSR) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Metsera, Inc. (MTSR) van 2023 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
| Jaar | Dividendrendement | Wijzigen |
|---|---|---|
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
| Bedrijf | Dividendrendement | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
